ArticleFrontiers in microbiology2020
Recombinant Human Adenovirus Type 5 Co-expressing RABV G and SFTSV Gn Induces Protective Immunity Against Rabies Virus and Severe Fever With Thrombocytopenia Syndrome Virus in Mice.
Article in Frontiers in microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 29 citations in OpenAlex.
- Evaluation of new adjuvants in enhancing the immune response to a candidate of Severe Fever with Thrombocytopenia Syndrome Virus vaccine.bioRxiv : the preprint server for biology · 2026Article
- Targeting the lethal weakness of SFTSV: Latest advances in antiviral strategies and immune prevention.iScience · 2026Review
- Recombinant Dabie bandavirus as a bivalent vaccine platform inducing protective immunity against intracellular pathogens and cancer.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Immunogenicity of a bivalent recombinant adenovirus expressing VP1 proteins of bovine norovirus and bovine nebovirus in mice and calves.BMC microbiology · 2025Article
- Protection Against Rabies Induced by the Non-Replicative Viral Vectors MVA and Ad5 Expressing Rabies Glycoprotein.Viruses · 2025Article
- Pair combinations of human monoclonal antibodies fully protected mice against bunyavirus SFTSV lethal challenge.PLoS pathogens · 2025Article
- Latest advances and prospects in the pathogenesis, animal models, and vaccine research of severe fever with thrombocytopenia syndrome virus.Frontiers in immunology · 2025Review
- Adenovirus type 5-expressing Gn induces better protective immunity than Gc against SFTSV infection in mice.NPJ vaccines · 2024Article
- Recent research advances in the development of Dabie Banda virus vaccines.PLoS neglected tropical diseases · 2024Review
- Vaccine Development for Severe Fever with Thrombocytopenia Syndrome Virus in Dogs.Journal of microbiology (Seoul, Korea) · 2024Article
- Potent immunogenicity and neutralization of recombinant adeno-associated virus expressing the glycoprotein of severe fever with thrombocytopenia virus.The Journal of veterinary medical science · 2024Article
- mRNA vaccine encoding Gn provides protection against severe fever with thrombocytopenia syndrome virus in mice.NPJ vaccines · 2023Article
- Emerging Tick-BorneMicroorganisms · 2023Review
- Heterologous vaccination utilizing viral vector and protein platforms confers complete protection against SFTSV.Scientific reports · 2023Article
- An mRNA-Based Multiple Antigenic Gene Expression System Delivered by EngineeredPharmaceutics · 2023Article
- Article
- Overview of the immunological mechanism underlying severe fever with thrombocytopenia syndrome (Review).International journal of molecular medicine · 2022Review
- Recovery of Two Replication-Competent Canine Distemper Viruses That Separately Express Dabie Bandavirus Gn and Gc.Frontiers in veterinary science · 2022Article
- Animal Model of Severe Fever With Thrombocytopenia Syndrome Virus Infection.Frontiers in microbiology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Both severe fever with thrombocytopenia syndrome (SFTS) and rabies are severe zoonotic diseases. As co-hosts of rabies virus (RABV) and SFTS virus (SFTSV), dogs and cats could not only be infected but also transmit the virus to human. Hence, developing a bivalent vaccine against both SFTS and rabies is urgently needed. In this study, we generated a recombinant replication-deficient human adenovirus type 5 (Ad5) co-expressing RABV G and SFTSV Gn (Ad5-G-Gn) and evaluated its immunogenicity and efficacy in mice. Ad5-G-Gn immunization activated more dendritic cells (DCs) and B cells in lymph nodes (LNs) and induced Th1-/Th2-mediated responses in splenocytes, leading to robust production of neutralizing antibodies against SFTSV and RABV. In addition, single dose of Ad5-G-Gn conferred mice complete protection against lethal RABV challenge and significantly reduced splenic SFTS viral load. Therefore, our data support further development of Ad5-G-Gn as a potential bivalent vaccine candidate against SFTS and rabies for dog and cat use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.